ScreenerHero

EIKNEikon Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · eikontx.com
11.39USD-5.16%Mkt Cap: 616.94M $P/E: —

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap616.94M $
Enterprise Value303.32M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-324.25M $
Revenue/Share—
Last Price11.39 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees384
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.70
PEG—
EV/EBITDA-0.96
EV/Revenue—
P/S—
P/B1.25
EPS (TTM)-5.34
EPS (Forward)-6.33
52W Range
7.90037% of range17.40
52W High17.40 USD
52W Low7.900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE36.89%
ROA-54.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-188.52M $
CapEx (TTM)46.74M $
FCF Margin—
FCF Yield—
Net Debt-278.96M $
Net Debt/EBITDA0.88
Balance Sheet
Debt/Equity-0.29
Current Ratio9.89
Quick Ratio9.61
Book Value/Sh8.615 USD
Cash/Share9.807 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.60 USD
Upside (mean)+116.0%
Target Range4.000 USD – 32.00 USD
$4.000+116.0% to mean$32.00
# Analysts5
Ownership
Shares Out.54.17M
Float29.87M
Insiders17.38%
Institutions69.18%
Short Interest
Short Ratio15.1d
Short % Float11.97%
Short % Out.9.01%
Shares Short4.88M
Short (prev mo.)4.63M
Technical
SMA 5010.17 (+12.0%)
SMA 20011.11 (+2.6%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)364.40K
Avg Vol (10d)617.80K
Technical Indicators
RSI (14)57.8
MACD0.3518
MACD Signal0.1442
MACD Hist.+0.2077
BB Upper11.88 USD
BB Middle10.10 USD
BB Lower8.319 USD
BB Width35.26%
ATR (14)1.046 USD
Vol Ratio (20d)1.20x